Transcription of Executive Summary SAGE October 2017, …
{{id}} {{{paragraph}}}
Example: quiz answers
Executive Summary SAGE October 2017, …
1 Executive Summary SAGE October 2017, Pneumococcal Conjugate Vaccine Session Introduction Currently, WHO has recommended the use of either a 10-valent or 13-valent pneumococcal conjugate vaccine (PCV10 and PCV13, respectively), for all infants worldwide. For routine immunization, WHO has recommended that PCV can be administered using either a 2p+1 or 3p+0 schedule , though 3p+1 schedules are also used in some countries[1]. A total of 141 countries have introduced PCV into their national immunization program, and 7 out of the 10 countries with the highest pneumococcal disease burden have recently introduced the vaccine[2]. Since the introduction of the first PCV (PCV7) in 2000, global reductions in pneumococcal disease burden in children under 5 years of age have been observed.
three key PCV issues: dosing schedule, product choice, and catch up immunization. The discussions held by the WG were framed around the following three questions:
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: